CYTK - Cytokinetics, Incorporated
Price:
--
--
|
CONSENSUS:
Buy
DETAILS
|
PRICE TARGET:
$99.92
DETAILS
HIGH:
$140.00
LOW:
$83.00
MEDIAN:
$99.00
CONSENSUS:
$99.92
UPSIDE:
29.87%
Institutional Holders (13F)
Insider Trading
| DATE | INSIDER | TITLE | TYPE | SHARES | PRICE | VALUE |
|---|---|---|---|---|---|---|
| 2026-05-19 | Malik Fady Ibraham | officer: EVP Research & Development | M-Exempt | 3,500 | $7.80 | $27K |
| 2026-05-19 | Malik Fady Ibraham | officer: EVP Research & Development | SELL | 3,500 | $75.69 | $265K |
| 2026-05-14 | Blum Robert I | director, officer: President & CEO | SELL | 7,500 | $77.92 | $584K |
| 2026-05-05 | Callos Andrew | officer: EVP, Chief Commercial Officer | M-Exempt | 11,333 | $39.13 | $443K |
| 2026-05-05 | Callos Andrew | officer: EVP, Chief Commercial Officer | SELL | 11,333 | $77.25 | $875K |
| 2026-05-05 | Lee Sung | officer: EVP, Chief Financial Officer | SELL | 23,906 | $76.87 | $1.8M |
| 2026-05-05 | Malik Fady Ibraham | officer: EVP Research & Development | M-Exempt | 3,500 | $7.80 | $27K |
| 2026-05-05 | Malik Fady Ibraham | officer: EVP Research & Development | SELL | 3,500 | $77.37 | $271K |
| 2026-05-05 | WIERENGA WENDELL | director | SELL | 4,032 | $75.00 | $302K |
| 2026-05-05 | WIERENGA WENDELL | director | M-Exempt | 4,032 | $12.40 | $50K |
| 2026-05-05 | HENDERSON JOHN T | director | M-Exempt | 20,000 | $7.61 | $152K |
| 2026-05-05 | HENDERSON JOHN T | director | SELL | 20,000 | $75.97 | $1.5M |
| 2026-05-01 | Callos Andrew | officer: EVP, Chief Commercial Officer | M-Exempt | 15,857 | $37.63 | $597K |
| 2026-05-01 | Callos Andrew | officer: EVP, Chief Commercial Officer | SELL | 15,857 | $65.00 | $1.0M |
| 2026-04-30 | Callos Andrew | officer: EVP, Chief Commercial Officer | M-Exempt | 15,000 | $23.26 | $349K |
| 2026-04-30 | Callos Andrew | officer: EVP, Chief Commercial Officer | SELL | 15,000 | $63.26 | $949K |
| 2026-04-29 | Blum Robert I | director, officer: President & CEO | SELL | 7,500 | $59.62 | $447K |
| 2026-04-21 | Malik Fady Ibraham | officer: EVP Research & Development | SELL | 3,500 | $65.69 | $230K |
| 2026-04-21 | Malik Fady Ibraham | officer: EVP Research & Development | M-Exempt | 3,500 | $7.80 | $27K |
| 2026-04-15 | Callos Andrew | officer: EVP, Chief Commercial Officer | SELL | 7,449 | $66.02 | $492K |
| 2026-04-15 | Kaye Edward M. MD | director | A-Award | 191 | $65.37 | $12K |
| 2026-04-15 | HENDERSON JOHN T | director | A-Award | 325 | $65.37 | $21K |
| 2026-04-15 | Blum Robert I | director, officer: President & CEO | SELL | 7,500 | $65.38 | $490K |
| 2026-04-15 | Wysenski Nancy | director | A-Award | 95 | $65.37 | $6K |
| 2026-04-15 | WIERENGA WENDELL | director | A-Award | 95 | $65.37 | $6K |